HMPL-453 + gemcitabine + cisplatin

**HMPL-453 + gemcitabine + cisplatin** is a combination regimen under investigation for the treatment of advanced solid tumors, especially those with fibroblast growth factor receptor (FGFR) gene alterations. HMPL-453 is a novel, highly selective, and potent small molecule inhibitor of fibroblast growth factor receptors 1, 2, and 3. It is being developed to target aberrant FGFR signaling, which contributes to tumor growth, angiogenesis, and resistance to anti-tumor therapies. In clinical trials, HMPL-453 is administered alongside two established chemotherapeutic agents: - **Gemcitabine**: a nucleoside analog that inhibits DNA synthesis. - **Cisplatin**: a platinum-based agent that causes DNA crosslinking and apoptosis. The combination aims to enhance anti-tumor efficacy in patients with advanced solid tumors or subtypes such as intrahepatic cholangiocarcinoma (IHCC), gastric cancer, and urothelial carcinoma, particularly those harboring FGFR gene alterations. The regimen is currently being evaluated in phase Ib/II studies to determine its safety, tolerability, pharmacokinetics, and preliminary efficacy[2][3][9].